A/H5N1 Vaccine in Healthy Children Aged 2-9 Years

NCT00133536 | Completed Phase 1

• 1 other identifier: 04-077
• Study Type: interventional
• Target: 157
• Locations: 1 country
• Sites: 4

Brief Summary

The purposes of this study are: to make sure that there are no serious side effects of an experimental inactivated influenza A/H5N1 vaccine in children; and to see how the body's immune system reacts to the vaccine. To look at the side effects, researchers will follow children closely after vaccination. To look at immune system responses, researchers will test the children's blood before and a number of times after vaccination. Participants will include up to 130 healthy children ages 2-9 years. Participants will be assigned to receive 2, up to 3 doses of vaccine, or placebo (inactive substance). Subjects will receive at least 2 doses of vaccine approximately 28 days apart. If data shows an enhanced immune response from a third vaccination, children will be offered a third dose of the vaccine. Participants will be involved in study related procedures for up to 13 months, including up to 6 study visits, plus a number of telephone calls.

Conditions

Influenza

Keywords

H5N1, Influenza, children

Outcome Measures

Primary Outcomes (3)

• Adverse event (AE) and serious adverse event (SAE) information (solicited in clinic and via memory aids, concomitant medications, and periodic targeted physical assessments.)

  Solicited AEs-reactogenicity following each vaccination. Unsolicited AEs-SAEs occurring during the length of the study, and nonserious events occurring 28 days after receipt of the 2nd (from enrollment) or 3rd dose of vaccine.

• Proportion of subjects achieving a serum neutralizing antibody titer of 1:40 against the influenza A/H5N1 virus.

  28 days after receipt of the 2nd dose of vaccine (Day 56).

• Geometric mean titer and the frequency of 4-fold or greater increases in hemagglutination inhibition and neutralizing antibody titers.

  28 days after receipt of the 2nd dose of vaccine (Day 56).

Secondary Outcomes (3)

• Proportion of subjects achieving a serum neutralizing antibody titer of 1:40 against the influenza A/H5N1 virus.

  1 and 6 months after receipt of first and third doses (if third dose will be administered [see study design]) of vaccine.

• Geometric mean titer and the frequency of 4-fold or greater increases in serum hemagglutination inhibition antibody titer.

  1 and 6 months after receipt of first and third (if third dose will be administered [see study design]) doses of vaccine.

• Development of serum antibody responses against antigenically drifted variants of influenza H5N1 virus.

  Blood samples for serum assays will be collected at day 0, approximately 1 month after each immunization, and approximately 6 months after the first immunization and third immunization (if provided).

Study Arms (2)

1

EXPERIMENTAL

100 subjects 45 mcg of influenza A/H5N1.

Biological: Influenza A/H5N1 Vaccine

2

PLACEBO COMPARATOR

20 subjects saline placebo.

Drug: Placebo

Interventions

Influenza A/H5N1 Vaccine BIOLOGICAL

Monovalent inactivated subvirion influenza H5N1 vaccine (derived from A/Vietnam/1203/04). Packaged in single-dose vials of 90 mcg/mL (0.7 mL/vial). Dosage 45 mcg/0.5 mL administered intramuscularly.

1

Placebo DRUG

Normal saline administered intramuscularly.

2

Eligibility Criteria

• Age: 2 Years - 9 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17)

You may qualify if:

• The subject must be male or female, aged 2 through 9 years at enrollment.
• The subject must be in good health (and not on any chronic medications), as determined by medical history and a history-directed targeted physical examination.
• Parents or guardians must be able to understand and comply with planned study procedures and be available for all study visits.
• Parents or guardians must provide written consent prior to initiation of any study procedures, and subject may provide written assent as appropriate.

You may not qualify if:

• The subject must not have a known allergy to eggs or other components of the vaccine or sensitivity or allergy to latex.
• The subject must not have a history of asthma or recurrent wheezing.
• The subject must not be undergoing immunosuppression as a result of an underlying illness or treatment.
• The subject must not have an active neoplastic disease or a history of any hematologic malignancy.
• The subject must not be using oral or parenteral steroids, inhaled steroids, or other immunosuppressive or cytotoxic drugs. Note: Subjects on nasal or topical steroids will be allowed to enroll in this study.
• The subject must not have a history of receiving immunoglobulin or other blood product within the 3 months prior to enrollment in this study.
• The subject must not have received any other licensed vaccines within 2 weeks (for inactivated vaccines) or 4 weeks (for live vaccines) prior to enrollment in this study.
• The subject must not have an acute or chronic medical condition that, in the opinion of the investigator, would render vaccination unsafe or would interfere with the evaluation of responses (these conditions include, but are not limited to, known chronic liver disease, significant renal disease, unstable or progressive neurological disorders, diabetes mellitus, and transplant recipients).
• The subject must not have a history of severe reactions following immunization with contemporary influenza virus vaccines.
• The subject must not have an acute illness, including an axillary temperature greater than 100 degrees F, within 3 days prior to vaccination.
• The subject must not have received an experimental vaccine or medication within one month prior to enrollment in this study, or expect to receive an experimental vaccine, medication, or blood product during the 13-month study period.
• The subject must not have any condition that would, in the opinion of the investigator, place them at an unacceptable risk of injury or render the subject unable to meet the requirements of the protocol.
• History of Guillain-Barré syndrome.
• The subject must not be participating concurrently in another clinical trial (either in active phase or in follow-up phase).

Sponsors & Collaborators

• National Institute of Allergy and Infectious Diseases (NIAID): lead

Study Sites (4)

UCLA Center For Vaccine Research

Torrance, California, 90502, United States

Location

University of Maryland Baltimore

Baltimore, Maryland, 21201, United States

Location

Saint Louis University

St Louis, Missouri, 63104, United States

Location

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, 45229-3039, United States

Location

MeSH Terms

Conditions

Influenza, Human; Influenza in Birds

Condition Hierarchy (Ancestors)

Respiratory Tract Infections; Infections; Orthomyxoviridae Infections; RNA Virus Infections; Virus Diseases; Respiratory Tract Diseases; Bird Diseases; Animal Diseases

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: NIH

Study Record Dates

• First Submitted: August 19, 2005
• First Posted: August 23, 2005
• Study Start: January 1, 2006
• Primary Completion: April 1, 2007
• Study Completion: April 1, 2007
• Last Updated: August 27, 2010

Record last verified: 2008-06

Locations

US (4)